H. Doehner

发表

therapy of younger patients with chronic lymphocytic leukemia Fludarabine plus cyclophosphamide versus fludarabine alone in first line

U. Jaeger, M. Hallek, S. Stilgenbauer, 2013 .

Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia

M. Buyse, R. Schlenk, M. Heuser, 2015 .

Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy.

C. Fiehn, S. Fruehauf, R. Haas, 1993, Acta haematologica.

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.

R. Schlenk, A. Ganser, A. Glasmacher, 2005 .

Valproic Acid (VPA) Achieves High Response Rates in Patients with Low-Risk Myelodysplastic Syndromes.

C. Steidl, U. Germing, R. Haas, 2005 .

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

M. Hallek, S. Stilgenbauer, D. Winkler, 2011 .

High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia

J. Downing, I. Radtke, L. Bullinger, 2010 .

Early and Risk-Adapted Therapy with Fludarabine in High-Risk Binet Stage A CLL Patients Prolongs Progression Free Survival but Not Overall Survival: Results of the CLL1 Protocol of the German CLL Study Group (GCLLSG).

M. Hallek, R. Busch, B. Eichhorst, 2007 .

Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group

M. Stauch, M. Hallek, S. Stilgenbauer, 2011 .

RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSG)

R. Schlenk, V. Gaidzik, A. Ganser, 2008 .

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

C. Bloomfield, E. Estey, W. Hiddemann, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression markers for genetic risk groups and survival in cronic lymphocytic leukemia

U. Jaeger, P. Lichter, S. Stilgenbauer, 2009 .

Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northern blot analysis.

A. Ho, H. Kluding, M. Doerner, 1994, Leukemia research.

Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence.

Francine E. Garrett-Bakelman, C. Mason, M. Li, 2021, Cancer discovery.

RHAMM/CD168-R3 Peptide Vaccination of HLA-A2+ Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).

K. Giannopoulos, G. Ritter, M. Schmitt, 2005 .

The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.

J. Roliński, A. Dmoszyńska, K. Giannopoulos, 2005 .

Response: Letters regarding Blood. 2008;111:5446-5456 by Hanson et al and Mulligan et al

E. Montserrat, B. Cheson, M. Hallek, 2009 .

Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab (FC-Cam) in Patients with Relapsed or Genetic High-Risk CLL: Final Analysis of the CLL2L Trial of the German CLL Study Group.

M. Hallek, S. Stilgenbauer, M. Ritgen, 2009 .

Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.

V. Diehl, N. Schmitz, A. Ho, 2004 .

Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group

J. Raemaekers, N. Schmitz, D. Niederwieser, 2016, Leukemia & lymphoma.

Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia

R. Schlenk, M. Voso, F. D'Alo', 2008, Leukemia.

Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG)

M. Hallek, S. Stilgenbauer, M. Kneba, 2014 .